Skip to main content
Arrow with DNA helix
 

Bringing Chemistry to Medicine Symposium


Thursday, July 22: Transcription Therapy
Friday, July 23: Frontiers in Chemical Biology

 
 

The Bringing Chemistry to Medicine symposium features thought leaders at the interface of chemical and biomedical sciences, working in areas spanning therapeutic regulation of transcription and chromatin, computational biology, and chemical biology. This year’s annual symposium features two themes: Transcription Therapy (Thursday, July 22) and Frontiers in Chemical Biology (Friday, July 23).

This virtual symposium, hosted by the St. Jude Department of Chemical Biology and Therapeutics and the St. Jude Comprehensive Cancer Center, is a component of the institution’s strategic objective to establish a global hub focused on the emerging field of transcription-targeted therapeutics.

To enable broad participation and interaction among trainees and scientists around the world, registration is free.

Register

 
 
 
 

Speakers

 
Madan Babu portrait

M. Madan Babu

St. Jude Children's Research Hospital

 
Suzanne Baker portrait

Suzanne J. Baker

St. Jude Children's Research Hospital

 
Jay Bradner portrait

James E. Bradner

Novartis Institutes for Biomedical Research

 
Andrea Califano portrait

Andrea Califano

Columbia University

 
Francesca Ciccarelli portrait

Francesca Ciccarelli

The Francis Crick Institute

 
Patrick Cramer portrait

Patrick Cramer

Max Planck Institute

 
Craig Crews portrait

Craig Crews

Yale University

 
Pedro R. Cutillas portrait

Pedro R. Cutillas

Cancer Research UK Barts Center

 
Cigall Kadoch portrait

Cigall Kadoch

Dana-Farber Cancer Institute, Harvard Medical School, and the Broad Institute of MIT and Harvard

 
William G. Kaelin portrait

William G. Kaelin, Jr

Dana-Farber Cancer Institute

 
Mitch Lazar portrait

Mitch Lazar

University of Pennsylvania

 
Jonathan Licht portrait

Jonathan Licht

University of Florida Health Cancer Center

 
Craig W. Lindsley portrait

Craig W. Lindsley

Vanderbilt University

 
Debora S. Marks portrait

Debora S. Marks

Broad Institute of MIT and Harvard, Harvard Medical School 

 
Marvin J. Miller portrait

Marvin J. Miller

University of Notre Dame

 
Anjana Rao portrait

Anjana Rao

La Jolla Institute for Immunology

 
Tobin Sosnick portrait

Tobin Sosnick

The University of Chicago

 
Professor Dame Janet Thornton portrait

Janet Thornton

The European Bioinformatics Institute

 
 

Agenda

Transcription Therapy logo

Thursday, July 22: Transcription Therapy

Agenda events and times are currently being planned. Please check back for scheduling developments.

 
Chemical Biology and Therapeutics Symposium logo

Friday, July 23: Frontiers in Chemical Biology

Agenda events and times are currently being planned. Please check back for scheduling developments.

Watch our Archived Lectures

In 2020, St. Jude hosted an exciting two-day event focused on Transcription Therapy and Chemical Biology and Therapeutics.

Watch our Transcription Therapy Lectures   watch

Watch our Chemical Biology Lectures   watch

Transcription Therapy at St. Jude

Over decades of research, scientists in the St. Jude Comprehensive Cancer Center and others have discovered that several pediatric cancers emerge due to disruption in chromatin and epigenetic states and dysfunctional transcriptional regulation. While gene regulation in general has long been considered “undruggable,” scientists in the St. Jude Department of Chemical Biology & Therapeutics (CBT) have created synthetic gene regulators and are devising new chemical approaches to inhibit or degrade malfunctioning components of chromatin and gene regulatory machineries. This work builds on the history of St. Jude as a pioneer in the therapeutic use of small molecules targeting gene regulation, most notably the application of glucocorticoid receptor agonists into chemotherapy regimens for pediatric patients with acute lymphoblastic lymphoma (ALL). The drugging of this transcription factor helped to dramatically increase overall survival rates for newly diagnosed ALL to 94% at St. Jude.

Learn more about transcription therapy at St. Jude    Learn more